70
Participants
Start Date
February 28, 2011
Primary Completion Date
March 31, 2014
Study Completion Date
March 31, 2014
BKM120
Novartis Investigative Site, Wilrijk
Novartis Investigative Site, Leuven
Novartis Investigative Site, Parkville
Novartis Investigative Site, Liège
Novartis Investigative Site, Berlin
Novartis Investigative Site, Berlin
Novartis Investigative Site, Milan
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Carolinas HealthCare Systems Blumenthal Cancer Center, Charlotte
Novartis Investigative Site, Toulouse
Novartis Investigative Site, Aviano
Sarah Cannon Research Institute SCRI (2), Nashville
Novartis Investigative Site, Bologna
Novartis Investigative Site, Valencia
Novartis Investigative Site, Valencia
Novartis Investigative Site, Cologne
Novartis Investigative Site, Mainz
Novartis Investigative Site, Lyon
Novartis Investigative Site, Le Mans
Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville
University of Oklahoma Health Sciences Center OU Health, Oklahoma City
Texas Oncology, P.A. Austin, Bedford
South Texas Oncology and Hematology, PA South Tex Onc, San Antonio
Novartis Investigative Site, Napoli
St. Joseph's Hospital & Medical Center St Joseph's, Phoenix
Cancer Care Northwest CC Northwest- Spokane South(3), Spokane
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Singapore
Novartis Investigative Site, Rio de Janeiro
Morristown Memorial Hospital MMH, Morristown
Novartis Investigative Site, Vancouver
Novartis Investigative Site, Hamilton
Novartis Investigative Site, Toronto
Novartis Investigative Site, Montreal
Novartis Investigative Site, Nice
Novartis Investigative Site, Roma
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Chuo-ku
Novartis Investigative Site, Minato-ku
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Barcelona
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY